BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820971214. [PMID: 33240396 DOI: 10.1177/1756284820971214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Caballol B, Gudiño V, Panes J, Salas A. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34365869 DOI: 10.1080/13543784.2021.1965122] [Reference Citation Analysis]
5 Lo Presti E, Di Mitri R, Mocciaro F, Di Stefano AB, Scibetta N, Unti E, Cicero G, Pecoraro G, Conte E, Dieli F, Meraviglia S. Characterization of γδ T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status. J Crohns Colitis 2019;13:873-83. [PMID: 30689780 DOI: 10.1093/ecco-jcc/jjz015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis 2019;25:410-20. [PMID: 30295781 DOI: 10.1093/ibd/izy307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
7 Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 2018;53:379-89. [PMID: 29523023 DOI: 10.1080/00365521.2018.1447597] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
8 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bäuerlein CA, Qureischi M, Mokhtari Z, Tabares P, Brede C, Jordán Garrote AL, Riedel SS, Chopra M, Reu S, Mottok A, Arellano-Viera E, Graf C, Kurzwart M, Schmiedgen K, Einsele H, Wölfl M, Schlegel PG, Beilhack A. A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease. Front Immunol 2020;11:593321. [PMID: 33584657 DOI: 10.3389/fimmu.2020.593321] [Reference Citation Analysis]
10 Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
11 Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018;3:790-802. [PMID: 30353856 DOI: 10.1016/S2468-1253(18)30265-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
12 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
13 Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol 2021;14:333-42. [PMID: 34466013 DOI: 10.2147/CEG.S293272] [Reference Citation Analysis]
14 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
15 Ivison S, Des Rosiers C, Lesage S, Rioux JD, Levings MK. Biomarker-guided stratification of autoimmune patients for biologic therapy. Current Opinion in Immunology 2017;49:56-63. [DOI: 10.1016/j.coi.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
16 Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, McBride J, Neurath MF, Zundler S. Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Front Pharmacol 2019;10:39. [PMID: 30774593 DOI: 10.3389/fphar.2019.00039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
17 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
18 De Galan C, Gonzales GB, Van Welden S, Tavernier SJ, Lobaton T, Van Moerkercke W, Strubbe B, Peeters H, Macken E, De Vos M, Laukens D, Hindryckx P. Role of integrin expression in the prediction of response to vedolizumab: A prospective real-life multicentre cohort study. Clin Transl Med 2022;12:e769. [PMID: 35384344 DOI: 10.1002/ctm2.769] [Reference Citation Analysis]
19 McCarthy NE, Eberl M. Human γδ T-Cell Control of Mucosal Immunity and Inflammation. Front Immunol 2018;9:985. [PMID: 29867962 DOI: 10.3389/fimmu.2018.00985] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
20 Binder M, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, Atreya R, Neufert C, Atreya I, Neurath MF, Zundler S. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases 2018;24:1237-50. [DOI: 10.1093/ibd/izy077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
21 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
22 Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
23 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Brubaker DK, Kumar MP, Chiswick EL, Gregg C, Starchenko A, Vega PN, Southard-Smith AN, Simmons AJ, Scoville EA, Coburn LA, Wilson KT, Lau KS, Lauffenburger DA. An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease. Sci Signal 2020;13:eaay3258. [PMID: 32753478 DOI: 10.1126/scisignal.aay3258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Zgajnar N, Jedlicka P, Bamias G, Rivera-Nieves J. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol 2021. [PMID: 34433904 DOI: 10.1038/s41385-021-00445-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
27 Zundler S, Becker E, Weidinger C, Siegmund B. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Front Immunol. 2017;8:891. [PMID: 28804488 DOI: 10.3389/fimmu.2017.00891] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
28 Cucinotta U, Dipasquale V, Costa S, Pellegrino S, Ramistella V, Romano C. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis. J Clin Pharm Ther 2021. [PMID: 34278581 DOI: 10.1111/jcpt.13494] [Reference Citation Analysis]